Portal de Periódicos da CAPES

Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma

2011; Wiley; Volume: 38; Issue: 8 Linguagem: Inglês

10.1111/j.1600-0560.2011.01718.x

1600-0560

Christian Bull, Marjan Mirzabeigi, William B. Laskin, Meghan Dubina, Tom Traczyc, Joan Guitart, Pedram Gerami,

Tumors and Oncological Cases

Journal of Cutaneous PathologyVolume 38, Issue 8 p. 631-635 Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma Christian Bull, Corresponding Author Christian Bull Department of Dermatopathology, Northwestern University, Chicago, IL, USAChristian Bull, MD, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, SwitzerlandTel: +41 442551111Fax: +41 442554403e-mail: christian.bull@usz.chSearch for more papers by this authorMarjan Mirzabeigi, Marjan Mirzabeigi Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorWilliam Laskin, William Laskin Department of Surgical Pathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorMeghan Dubina, Meghan Dubina Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorTom Traczyc, Tom Traczyc Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorJoan Guitart, Joan Guitart Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorPedram Gerami, Pedram Gerami Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this author Christian Bull, Corresponding Author Christian Bull Department of Dermatopathology, Northwestern University, Chicago, IL, USAChristian Bull, MD, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, SwitzerlandTel: +41 442551111Fax: +41 442554403e-mail: christian.bull@usz.chSearch for more papers by this authorMarjan Mirzabeigi, Marjan Mirzabeigi Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorWilliam Laskin, William Laskin Department of Surgical Pathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorMeghan Dubina, Meghan Dubina Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorTom Traczyc, Tom Traczyc Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorJoan Guitart, Joan Guitart Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this authorPedram Gerami, Pedram Gerami Department of Dermatopathology, Northwestern University, Chicago, IL, USASearch for more papers by this author First published: 30 May 2011 https://doi.org/10.1111/j.1600-0560.2011.01718.xCitations: 12Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Background: Atypical fibroxanthoma (AFX) is a locally destructive, dermal-based, fibrohistiocytic, mesenchymal tumor. Immunohistochemistry helps to differentiate AFX from squamous cell carcinoma and spindle cell melanoma. Immunomarkers against p75 yield positive stains in spindled cell melanomas and negative stains in AFX, suggesting that these may be useful in differentiating these two entities. However, a recent study concluded that p75 is not a specific marker of neuroectodermal tumors; furthermore, p75 staining in AFX has only been evaluated in a few cases. Methods: We stained 20 AFXs for p75 and various other markers. Results: Reactivity was noted for vimentin (20 of 20 cases), CD10 (17/20), CD68 (14/20), CD99 (13/20), D2-40 (10/20) and p75 (1/20). Conclusions: We confirmed that CD99 and CD10 are frequently expressed in AFX (65 and 85%, respectively) and that CD31 rarely stains positive (5%). The 50% positivity rate of D2-40, in contrast with published evidence for its absence in melanoma, suggests that D2-40 may be useful for distinguishing AFX from melanoma. Furthermore, because only one sample was positive for p75, we confirm that p75 is useful in differentiating AFX from spindle cell melanoma. We advocate adding p75 and D2-40 to assist in differentiating AFX from melanoma. Bull C, Mirzabeigi M, Laskin W, Dubina M, Traczyc T, Guitart J, Gerami P. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma. Citing Literature Volume38, Issue8August 2011Pages 631-635 RelatedInformation